AstraZeneca aims to sell flu vaccine in EU
AstraZeneca said its MedImmune biologics unit has submitted a marketing application for its nasal spray live attenuated influenza vaccine (LAIV) to the European Medicines Agency.
Priory, Four Seasons merger talks collapse
The future of Four Seasons Health Care, one of Britain's biggest nursing home companies, has been thrown into doubt following the collapse of merger talks with the Priory Group.
Intercytex to acquire stem cell company Axordia
Intercytex, a leading developer of regenerative medicine products, said on December 22, it will issue seven million new shares to buy stem cell specialist Axordia.
Skyepharma ends U.S. Certihaler talks
SkyePharma plc said talks about the U.S. commercialisation of its asthma treatment Certihaler have ended after advisors to the Food and Drug Administration (FDA) questioned the benefits of the drug.
Tibotec Pharmaceuticals recruiting for trials of TMC278
Tibotec Pharmaceuticals is currently recruiting across Europe for two major phase III efficacy trials of its HIV drug TMC278.
Lundbeck initiates trials of nalmefene
H Lundbeck AS is continuing development of nalmefene for the treatment of alcoholism, initiating three phase III clinical trials with the compound.